SrasV1, PascalFrancis, Corpus, bibRecord, 000004

Repurposing of Clinically Developed Drugs for Treatment of Middle East Respiratory Syndrome Coronavirus Infection

Identifieur interne : 000004 ( PascalFrancis/Corpus ); précédent : 000003; suivant : 000005

Repurposing of Clinically Developed Drugs for Treatment of Middle East Respiratory Syndrome Coronavirus Infection

Auteurs : Julie Dyall ; Christopher M. Coleman ; Brit J. Hart ; Thiagarajan Venkataraman ; Michael R. Holbrook ; Jason Kindrachuk ; Reed F. Johnson ; Gene G. Jr Olinger ; Peter B. Jahrling ; Monique Laidlaw ; Lisa M. Johansen ; Calli M. Lear-Rooney ; Pamela J. Glass ; Lisa E. Hensley ; Matthew B. Frieman

Source :

Antimicrobial agents and chemotherapy [ 0066-4804 ] ; 2014.

RBID : Pascal:14-0220025

Descripteurs français

Pascal (Inist)
- Autorisation mise sur marché, Indication, Chimiothérapie, Coronavirus, Infection, Repositionnement, Syndrome respiratoire du Moyen-Orient.

English descriptors

KwdEn :
- Chemotherapy, Coronavirus, Indication, Infection, Marketing authorization, Middle East respiratory syndrome.

Abstract

Outbreaks of emerging infections present health professionals with the unique challenge of trying to select appropriate pharmacologic treatments in the clinic with little time available for drug testing and development. Typically, clinicians are left with general supportive care and often untested convalescent-phase plasma as available treatment options. Repurposing of approved pharmaceutical drugs for new indications presents an attractive alternative to clinicians, researchers, public health agencies, drug developers, and funding agencies. Given the development times and manufacturing requirements for new products, repurposing of existing drugs is likely the only solution for outbreaks due to emerging viruses. In the studies described here, a library of 290 compounds was screened for antiviral activity against Middle East respiratory syndrome coronavirus (MERS-CoV) and severe acute respiratory syndrome coronavirus (SARS-CoV). Selection of compounds for inclusion in the library was dependent on current or previous FDA approval or advanced clinical development. Some drugs that had a well-defined cellular pathway as target were included. In total, 27 compounds with activity against both MERS-CoV and SARS-CoV were identified. The compounds belong to 13 different classes of pharmaceuticals, including inhibitors of estrogen receptors used for cancer treatment and inhibitors of dopamine receptor used as antipsychotics. The drugs identified in these screens provide new targets for in vivo studies as well as incorporation into ongoing clinical studies.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0066-4804`
A02	`01`			`@0 AACHAX`
A03		`1`		`@0 Antimicrob. agents chemother.`
A05				`@2 58`
A06				`@2 8`
A08	`01`	`1`	`ENG`	`@1 Repurposing of Clinically Developed Drugs for Treatment of Middle East Respiratory Syndrome Coronavirus Infection`
A11	`01`	`1`		`@1 DYALL (Julie)`
A11	`02`	`1`		`@1 COLEMAN (Christopher M.)`
A11	`03`	`1`		`@1 HART (Brit J.)`
A11	`04`	`1`		`@1 VENKATARAMAN (Thiagarajan)`
A11	`05`	`1`		`@1 HOLBROOK (Michael R.)`
A11	`06`	`1`		`@1 KINDRACHUK (Jason)`
A11	`07`	`1`		`@1 JOHNSON (Reed F.)`
A11	`08`	`1`		`@1 OLINGER (Gene G. JR)`
A11	`09`	`1`		`@1 JAHRLING (Peter B.)`
A11	`10`	`1`		`@1 LAIDLAW (Monique)`
A11	`11`	`1`		`@1 JOHANSEN (Lisa M.)`
A11	`12`	`1`		`@1 LEAR-ROONEY (Calli M.)`
A11	`13`	`1`		`@1 GLASS (Pamela J.)`
A11	`14`	`1`		`@1 HENSLEY (Lisa E.)`
A11	`15`	`1`		`@1 FRIEMAN (Matthew B.)`
A14	`01`			`@1 Integrated Research Facility, National Institute of Allergy and Infectious Diseases, National Institutes of Health @2 Frederick, Maryland @3 USA @Z 1 aut. @Z 3 aut. @Z 5 aut. @Z 6 aut. @Z 8 aut. @Z 9 aut. @Z 14 aut.`
A14	`02`			`@1 Department of Microbiology and Immunology, University of Maryland School of Medicine @2 Baltimore, Maryland @3 USA @Z 2 aut. @Z 4 aut. @Z 15 aut.`
A14	`03`			`@1 Emerging Viral Pathogens Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health @2 Frederick, Maryland @3 USA @Z 7 aut. @Z 9 aut.`
A14	`04`			`@1 Zalicus Inc. @2 Cambridge, Massachusetts @3 USA @Z 10 aut. @Z 11 aut.`
A14	`05`			`@1 United States Army Medical Research Institute of Infectious Diseases @2 Frederick, Maryland @3 USA @Z 12 aut. @Z 13 aut.`
A20				`@1 4885-4893`
A21				`@1 2014`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 13334 @5 354000504837190740`
A44				`@0 0000 @1 © 2014 INIST-CNRS. All rights reserved.`
A45				`@0 48 ref.`
A47	`01`	`1`		`@0 14-0220025`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Antimicrobial agents and chemotherapy`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 Outbreaks of emerging infections present health professionals with the unique challenge of trying to select appropriate pharmacologic treatments in the clinic with little time available for drug testing and development. Typically, clinicians are left with general supportive care and often untested convalescent-phase plasma as available treatment options. Repurposing of approved pharmaceutical drugs for new indications presents an attractive alternative to clinicians, researchers, public health agencies, drug developers, and funding agencies. Given the development times and manufacturing requirements for new products, repurposing of existing drugs is likely the only solution for outbreaks due to emerging viruses. In the studies described here, a library of 290 compounds was screened for antiviral activity against Middle East respiratory syndrome coronavirus (MERS-CoV) and severe acute respiratory syndrome coronavirus (SARS-CoV). Selection of compounds for inclusion in the library was dependent on current or previous FDA approval or advanced clinical development. Some drugs that had a well-defined cellular pathway as target were included. In total, 27 compounds with activity against both MERS-CoV and SARS-CoV were identified. The compounds belong to 13 different classes of pharmaceuticals, including inhibitors of estrogen receptors used for cancer treatment and inhibitors of dopamine receptor used as antipsychotics. The drugs identified in these screens provide new targets for in vivo studies as well as incorporation into ongoing clinical studies.
C02	`01`	`X`		`@0 002B02S`
C02	`02`	`X`		`@0 002B05C02C`
C03	`01`	`X`	`FRE`	`@0 Autorisation mise sur marché @5 01`
C03	`01`	`X`	`ENG`	`@0 Marketing authorization @5 01`
C03	`01`	`X`	`SPA`	`@0 Autorisación comercialización @5 01`
C03	`02`	`X`	`FRE`	`@0 Indication @5 02`
C03	`02`	`X`	`ENG`	`@0 Indication @5 02`
C03	`02`	`X`	`SPA`	`@0 Indicación @5 02`
C03	`03`	`X`	`FRE`	`@0 Chimiothérapie @5 03`
C03	`03`	`X`	`ENG`	`@0 Chemotherapy @5 03`
C03	`03`	`X`	`SPA`	`@0 Quimioterapia @5 03`
C03	`04`	`X`	`FRE`	`@0 Coronavirus @2 NW @5 04`
C03	`04`	`X`	`ENG`	`@0 Coronavirus @2 NW @5 04`
C03	`04`	`X`	`SPA`	`@0 Coronavirus @2 NW @5 04`
C03	`05`	`X`	`FRE`	`@0 Infection @5 05`
C03	`05`	`X`	`ENG`	`@0 Infection @5 05`
C03	`05`	`X`	`SPA`	`@0 Infección @5 05`
C03	`06`	`X`	`FRE`	`@0 Repositionnement @4 INC @5 86`
C03	`07`	`X`	`FRE`	`@0 Syndrome respiratoire du Moyen-Orient @4 CD @5 96`
C03	`07`	`X`	`ENG`	`@0 Middle East respiratory syndrome @4 CD @5 96`
C07	`01`	`X`	`FRE`	`@0 Traitement`
C07	`01`	`X`	`ENG`	`@0 Treatment`
C07	`01`	`X`	`SPA`	`@0 Tratamiento`
C07	`02`	`X`	`FRE`	`@0 Coronaviridae @2 NW`
C07	`02`	`X`	`ENG`	`@0 Coronaviridae @2 NW`
C07	`02`	`X`	`SPA`	`@0 Coronaviridae @2 NW`
C07	`03`	`X`	`FRE`	`@0 Nidovirales @2 NW`
C07	`03`	`X`	`ENG`	`@0 Nidovirales @2 NW`
C07	`03`	`X`	`SPA`	`@0 Nidovirales @2 NW`
C07	`04`	`X`	`FRE`	`@0 Virus @2 NW`
C07	`04`	`X`	`ENG`	`@0 Virus @2 NW`
C07	`04`	`X`	`SPA`	`@0 Virus @2 NW`
C07	`05`	`X`	`FRE`	`@0 Pathologie de l'appareil respiratoire @5 37`
C07	`05`	`X`	`ENG`	`@0 Respiratory disease @5 37`
C07	`05`	`X`	`SPA`	`@0 Aparato respiratorio patología @5 37`
C07	`06`	`X`	`FRE`	`@0 Virose @5 38`
C07	`06`	`X`	`ENG`	`@0 Viral disease @5 38`
C07	`06`	`X`	`SPA`	`@0 Virosis @5 38`
N21				`@1 265`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Format Inist (serveur)

NO :	PASCAL 14-0220025 INIST
ET :	Repurposing of Clinically Developed Drugs for Treatment of Middle East Respiratory Syndrome Coronavirus Infection
AU :	DYALL (Julie); COLEMAN (Christopher M.); HART (Brit J.); VENKATARAMAN (Thiagarajan); HOLBROOK (Michael R.); KINDRACHUK (Jason); JOHNSON (Reed F.); OLINGER (Gene G. JR); JAHRLING (Peter B.); LAIDLAW (Monique); JOHANSEN (Lisa M.); LEAR-ROONEY (Calli M.); GLASS (Pamela J.); HENSLEY (Lisa E.); FRIEMAN (Matthew B.)
AF :	Integrated Research Facility, National Institute of Allergy and Infectious Diseases, National Institutes of Health/Frederick, Maryland/Etats-Unis (1 aut., 3 aut., 5 aut., 6 aut., 8 aut., 9 aut., 14 aut.); Department of Microbiology and Immunology, University of Maryland School of Medicine/Baltimore, Maryland/Etats-Unis (2 aut., 4 aut., 15 aut.); Emerging Viral Pathogens Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health/Frederick, Maryland/Etats-Unis (7 aut., 9 aut.); Zalicus Inc./Cambridge, Massachusetts/Etats-Unis (10 aut., 11 aut.); United States Army Medical Research Institute of Infectious Diseases/Frederick, Maryland/Etats-Unis (12 aut., 13 aut.)
DT :	Publication en série; Niveau analytique
SO :	Antimicrobial agents and chemotherapy; ISSN 0066-4804; Coden AACHAX; Etats-Unis; Da. 2014; Vol. 58; No. 8; Pp. 4885-4893; Bibl. 48 ref.
LA :	Anglais
EA :	Outbreaks of emerging infections present health professionals with the unique challenge of trying to select appropriate pharmacologic treatments in the clinic with little time available for drug testing and development. Typically, clinicians are left with general supportive care and often untested convalescent-phase plasma as available treatment options. Repurposing of approved pharmaceutical drugs for new indications presents an attractive alternative to clinicians, researchers, public health agencies, drug developers, and funding agencies. Given the development times and manufacturing requirements for new products, repurposing of existing drugs is likely the only solution for outbreaks due to emerging viruses. In the studies described here, a library of 290 compounds was screened for antiviral activity against Middle East respiratory syndrome coronavirus (MERS-CoV) and severe acute respiratory syndrome coronavirus (SARS-CoV). Selection of compounds for inclusion in the library was dependent on current or previous FDA approval or advanced clinical development. Some drugs that had a well-defined cellular pathway as target were included. In total, 27 compounds with activity against both MERS-CoV and SARS-CoV were identified. The compounds belong to 13 different classes of pharmaceuticals, including inhibitors of estrogen receptors used for cancer treatment and inhibitors of dopamine receptor used as antipsychotics. The drugs identified in these screens provide new targets for in vivo studies as well as incorporation into ongoing clinical studies.
CC :	002B02S; 002B05C02C
FD :	Autorisation mise sur marché; Indication; Chimiothérapie; Coronavirus; Infection; Repositionnement; Syndrome respiratoire du Moyen-Orient
FG :	Traitement; Coronaviridae; Nidovirales; Virus; Pathologie de l'appareil respiratoire; Virose
ED :	Marketing authorization; Indication; Chemotherapy; Coronavirus; Infection; Middle East respiratory syndrome
EG :	Treatment; Coronaviridae; Nidovirales; Virus; Respiratory disease; Viral disease
SD :	Autorisación comercialización; Indicación; Quimioterapia; Coronavirus; Infección
LO :	INIST-13334.354000504837190740
ID :	14-0220025

Links to Exploration step

Pascal:14-0220025

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Repurposing of Clinically Developed Drugs for Treatment of Middle East Respiratory Syndrome Coronavirus Infection</title>
<author><name sortKey="Dyall, Julie" sort="Dyall, Julie" uniqKey="Dyall J" first="Julie" last="Dyall">Julie Dyall</name>
<affiliation><inist:fA14 i1="01"><s1>Integrated Research Facility, National Institute of Allergy and Infectious Diseases, National Institutes of Health</s1>
<s2>Frederick, Maryland</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>14 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Coleman, Christopher M" sort="Coleman, Christopher M" uniqKey="Coleman C" first="Christopher M." last="Coleman">Christopher M. Coleman</name>
<affiliation><inist:fA14 i1="02"><s1>Department of Microbiology and Immunology, University of Maryland School of Medicine</s1>
<s2>Baltimore, Maryland</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>15 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Hart, Brit J" sort="Hart, Brit J" uniqKey="Hart B" first="Brit J." last="Hart">Brit J. Hart</name>
<affiliation><inist:fA14 i1="01"><s1>Integrated Research Facility, National Institute of Allergy and Infectious Diseases, National Institutes of Health</s1>
<s2>Frederick, Maryland</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>14 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Venkataraman, Thiagarajan" sort="Venkataraman, Thiagarajan" uniqKey="Venkataraman T" first="Thiagarajan" last="Venkataraman">Thiagarajan Venkataraman</name>
<affiliation><inist:fA14 i1="02"><s1>Department of Microbiology and Immunology, University of Maryland School of Medicine</s1>
<s2>Baltimore, Maryland</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>15 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Holbrook, Michael R" sort="Holbrook, Michael R" uniqKey="Holbrook M" first="Michael R." last="Holbrook">Michael R. Holbrook</name>
<affiliation><inist:fA14 i1="01"><s1>Integrated Research Facility, National Institute of Allergy and Infectious Diseases, National Institutes of Health</s1>
<s2>Frederick, Maryland</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>14 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Kindrachuk, Jason" sort="Kindrachuk, Jason" uniqKey="Kindrachuk J" first="Jason" last="Kindrachuk">Jason Kindrachuk</name>
<affiliation><inist:fA14 i1="01"><s1>Integrated Research Facility, National Institute of Allergy and Infectious Diseases, National Institutes of Health</s1>
<s2>Frederick, Maryland</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>14 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Johnson, Reed F" sort="Johnson, Reed F" uniqKey="Johnson R" first="Reed F." last="Johnson">Reed F. Johnson</name>
<affiliation><inist:fA14 i1="03"><s1>Emerging Viral Pathogens Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health</s1>
<s2>Frederick, Maryland</s2>
<s3>USA</s3>
<sZ>7 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Olinger, Gene G Jr" sort="Olinger, Gene G Jr" uniqKey="Olinger G" first="Gene G. Jr" last="Olinger">Gene G. Jr Olinger</name>
<affiliation><inist:fA14 i1="01"><s1>Integrated Research Facility, National Institute of Allergy and Infectious Diseases, National Institutes of Health</s1>
<s2>Frederick, Maryland</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>14 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Jahrling, Peter B" sort="Jahrling, Peter B" uniqKey="Jahrling P" first="Peter B." last="Jahrling">Peter B. Jahrling</name>
<affiliation><inist:fA14 i1="01"><s1>Integrated Research Facility, National Institute of Allergy and Infectious Diseases, National Institutes of Health</s1>
<s2>Frederick, Maryland</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>14 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="03"><s1>Emerging Viral Pathogens Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health</s1>
<s2>Frederick, Maryland</s2>
<s3>USA</s3>
<sZ>7 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Laidlaw, Monique" sort="Laidlaw, Monique" uniqKey="Laidlaw M" first="Monique" last="Laidlaw">Monique Laidlaw</name>
<affiliation><inist:fA14 i1="04"><s1>Zalicus Inc.</s1>
<s2>Cambridge, Massachusetts</s2>
<s3>USA</s3>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Johansen, Lisa M" sort="Johansen, Lisa M" uniqKey="Johansen L" first="Lisa M." last="Johansen">Lisa M. Johansen</name>
<affiliation><inist:fA14 i1="04"><s1>Zalicus Inc.</s1>
<s2>Cambridge, Massachusetts</s2>
<s3>USA</s3>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Lear Rooney, Calli M" sort="Lear Rooney, Calli M" uniqKey="Lear Rooney C" first="Calli M." last="Lear-Rooney">Calli M. Lear-Rooney</name>
<affiliation><inist:fA14 i1="05"><s1>United States Army Medical Research Institute of Infectious Diseases</s1>
<s2>Frederick, Maryland</s2>
<s3>USA</s3>
<sZ>12 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Glass, Pamela J" sort="Glass, Pamela J" uniqKey="Glass P" first="Pamela J." last="Glass">Pamela J. Glass</name>
<affiliation><inist:fA14 i1="05"><s1>United States Army Medical Research Institute of Infectious Diseases</s1>
<s2>Frederick, Maryland</s2>
<s3>USA</s3>
<sZ>12 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Hensley, Lisa E" sort="Hensley, Lisa E" uniqKey="Hensley L" first="Lisa E." last="Hensley">Lisa E. Hensley</name>
<affiliation><inist:fA14 i1="01"><s1>Integrated Research Facility, National Institute of Allergy and Infectious Diseases, National Institutes of Health</s1>
<s2>Frederick, Maryland</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>14 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Frieman, Matthew B" sort="Frieman, Matthew B" uniqKey="Frieman M" first="Matthew B." last="Frieman">Matthew B. Frieman</name>
<affiliation><inist:fA14 i1="02"><s1>Department of Microbiology and Immunology, University of Maryland School of Medicine</s1>
<s2>Baltimore, Maryland</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>15 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">14-0220025</idno>
<date when="2014">2014</date>
<idno type="stanalyst">PASCAL 14-0220025 INIST</idno>
<idno type="RBID">Pascal:14-0220025</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000004</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Repurposing of Clinically Developed Drugs for Treatment of Middle East Respiratory Syndrome Coronavirus Infection</title>
<author><name sortKey="Dyall, Julie" sort="Dyall, Julie" uniqKey="Dyall J" first="Julie" last="Dyall">Julie Dyall</name>
<affiliation><inist:fA14 i1="01"><s1>Integrated Research Facility, National Institute of Allergy and Infectious Diseases, National Institutes of Health</s1>
<s2>Frederick, Maryland</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>14 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Coleman, Christopher M" sort="Coleman, Christopher M" uniqKey="Coleman C" first="Christopher M." last="Coleman">Christopher M. Coleman</name>
<affiliation><inist:fA14 i1="02"><s1>Department of Microbiology and Immunology, University of Maryland School of Medicine</s1>
<s2>Baltimore, Maryland</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>15 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Hart, Brit J" sort="Hart, Brit J" uniqKey="Hart B" first="Brit J." last="Hart">Brit J. Hart</name>
<affiliation><inist:fA14 i1="01"><s1>Integrated Research Facility, National Institute of Allergy and Infectious Diseases, National Institutes of Health</s1>
<s2>Frederick, Maryland</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>14 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Venkataraman, Thiagarajan" sort="Venkataraman, Thiagarajan" uniqKey="Venkataraman T" first="Thiagarajan" last="Venkataraman">Thiagarajan Venkataraman</name>
<affiliation><inist:fA14 i1="02"><s1>Department of Microbiology and Immunology, University of Maryland School of Medicine</s1>
<s2>Baltimore, Maryland</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>15 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Holbrook, Michael R" sort="Holbrook, Michael R" uniqKey="Holbrook M" first="Michael R." last="Holbrook">Michael R. Holbrook</name>
<affiliation><inist:fA14 i1="01"><s1>Integrated Research Facility, National Institute of Allergy and Infectious Diseases, National Institutes of Health</s1>
<s2>Frederick, Maryland</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>14 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Kindrachuk, Jason" sort="Kindrachuk, Jason" uniqKey="Kindrachuk J" first="Jason" last="Kindrachuk">Jason Kindrachuk</name>
<affiliation><inist:fA14 i1="01"><s1>Integrated Research Facility, National Institute of Allergy and Infectious Diseases, National Institutes of Health</s1>
<s2>Frederick, Maryland</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>14 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Johnson, Reed F" sort="Johnson, Reed F" uniqKey="Johnson R" first="Reed F." last="Johnson">Reed F. Johnson</name>
<affiliation><inist:fA14 i1="03"><s1>Emerging Viral Pathogens Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health</s1>
<s2>Frederick, Maryland</s2>
<s3>USA</s3>
<sZ>7 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Olinger, Gene G Jr" sort="Olinger, Gene G Jr" uniqKey="Olinger G" first="Gene G. Jr" last="Olinger">Gene G. Jr Olinger</name>
<affiliation><inist:fA14 i1="01"><s1>Integrated Research Facility, National Institute of Allergy and Infectious Diseases, National Institutes of Health</s1>
<s2>Frederick, Maryland</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>14 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Jahrling, Peter B" sort="Jahrling, Peter B" uniqKey="Jahrling P" first="Peter B." last="Jahrling">Peter B. Jahrling</name>
<affiliation><inist:fA14 i1="01"><s1>Integrated Research Facility, National Institute of Allergy and Infectious Diseases, National Institutes of Health</s1>
<s2>Frederick, Maryland</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>14 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="03"><s1>Emerging Viral Pathogens Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health</s1>
<s2>Frederick, Maryland</s2>
<s3>USA</s3>
<sZ>7 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Laidlaw, Monique" sort="Laidlaw, Monique" uniqKey="Laidlaw M" first="Monique" last="Laidlaw">Monique Laidlaw</name>
<affiliation><inist:fA14 i1="04"><s1>Zalicus Inc.</s1>
<s2>Cambridge, Massachusetts</s2>
<s3>USA</s3>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Johansen, Lisa M" sort="Johansen, Lisa M" uniqKey="Johansen L" first="Lisa M." last="Johansen">Lisa M. Johansen</name>
<affiliation><inist:fA14 i1="04"><s1>Zalicus Inc.</s1>
<s2>Cambridge, Massachusetts</s2>
<s3>USA</s3>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Lear Rooney, Calli M" sort="Lear Rooney, Calli M" uniqKey="Lear Rooney C" first="Calli M." last="Lear-Rooney">Calli M. Lear-Rooney</name>
<affiliation><inist:fA14 i1="05"><s1>United States Army Medical Research Institute of Infectious Diseases</s1>
<s2>Frederick, Maryland</s2>
<s3>USA</s3>
<sZ>12 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Glass, Pamela J" sort="Glass, Pamela J" uniqKey="Glass P" first="Pamela J." last="Glass">Pamela J. Glass</name>
<affiliation><inist:fA14 i1="05"><s1>United States Army Medical Research Institute of Infectious Diseases</s1>
<s2>Frederick, Maryland</s2>
<s3>USA</s3>
<sZ>12 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Hensley, Lisa E" sort="Hensley, Lisa E" uniqKey="Hensley L" first="Lisa E." last="Hensley">Lisa E. Hensley</name>
<affiliation><inist:fA14 i1="01"><s1>Integrated Research Facility, National Institute of Allergy and Infectious Diseases, National Institutes of Health</s1>
<s2>Frederick, Maryland</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>14 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Frieman, Matthew B" sort="Frieman, Matthew B" uniqKey="Frieman M" first="Matthew B." last="Frieman">Matthew B. Frieman</name>
<affiliation><inist:fA14 i1="02"><s1>Department of Microbiology and Immunology, University of Maryland School of Medicine</s1>
<s2>Baltimore, Maryland</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>15 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Antimicrobial agents and chemotherapy</title>
<title level="j" type="abbreviated">Antimicrob. agents chemother.</title>
<idno type="ISSN">0066-4804</idno>
<imprint><date when="2014">2014</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Antimicrobial agents and chemotherapy</title>
<title level="j" type="abbreviated">Antimicrob. agents chemother.</title>
<idno type="ISSN">0066-4804</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Chemotherapy</term>
<term>Coronavirus</term>
<term>Indication</term>
<term>Infection</term>
<term>Marketing authorization</term>
<term>Middle East respiratory syndrome</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Autorisation mise sur marché</term>
<term>Indication</term>
<term>Chimiothérapie</term>
<term>Coronavirus</term>
<term>Infection</term>
<term>Repositionnement</term>
<term>Syndrome respiratoire du Moyen-Orient</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Outbreaks of emerging infections present health professionals with the unique challenge of trying to select appropriate pharmacologic treatments in the clinic with little time available for drug testing and development. Typically, clinicians are left with general supportive care and often untested convalescent-phase plasma as available treatment options. Repurposing of approved pharmaceutical drugs for new indications presents an attractive alternative to clinicians, researchers, public health agencies, drug developers, and funding agencies. Given the development times and manufacturing requirements for new products, repurposing of existing drugs is likely the only solution for outbreaks due to emerging viruses. In the studies described here, a library of 290 compounds was screened for antiviral activity against Middle East respiratory syndrome coronavirus (MERS-CoV) and severe acute respiratory syndrome coronavirus (SARS-CoV). Selection of compounds for inclusion in the library was dependent on current or previous FDA approval or advanced clinical development. Some drugs that had a well-defined cellular pathway as target were included. In total, 27 compounds with activity against both MERS-CoV and SARS-CoV were identified. The compounds belong to 13 different classes of pharmaceuticals, including inhibitors of estrogen receptors used for cancer treatment and inhibitors of dopamine receptor used as antipsychotics. The drugs identified in these screens provide new targets for in vivo studies as well as incorporation into ongoing clinical studies.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0066-4804</s0>
</fA01>
<fA02 i1="01"><s0>AACHAX</s0>
</fA02>
<fA03 i2="1"><s0>Antimicrob. agents chemother.</s0>
</fA03>
<fA05><s2>58</s2>
</fA05>
<fA06><s2>8</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Repurposing of Clinically Developed Drugs for Treatment of Middle East Respiratory Syndrome Coronavirus Infection</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>DYALL (Julie)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>COLEMAN (Christopher M.)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>HART (Brit J.)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>VENKATARAMAN (Thiagarajan)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>HOLBROOK (Michael R.)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>KINDRACHUK (Jason)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>JOHNSON (Reed F.)</s1>
</fA11>
<fA11 i1="08" i2="1"><s1>OLINGER (Gene G. JR)</s1>
</fA11>
<fA11 i1="09" i2="1"><s1>JAHRLING (Peter B.)</s1>
</fA11>
<fA11 i1="10" i2="1"><s1>LAIDLAW (Monique)</s1>
</fA11>
<fA11 i1="11" i2="1"><s1>JOHANSEN (Lisa M.)</s1>
</fA11>
<fA11 i1="12" i2="1"><s1>LEAR-ROONEY (Calli M.)</s1>
</fA11>
<fA11 i1="13" i2="1"><s1>GLASS (Pamela J.)</s1>
</fA11>
<fA11 i1="14" i2="1"><s1>HENSLEY (Lisa E.)</s1>
</fA11>
<fA11 i1="15" i2="1"><s1>FRIEMAN (Matthew B.)</s1>
</fA11>
<fA14 i1="01"><s1>Integrated Research Facility, National Institute of Allergy and Infectious Diseases, National Institutes of Health</s1>
<s2>Frederick, Maryland</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>14 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Department of Microbiology and Immunology, University of Maryland School of Medicine</s1>
<s2>Baltimore, Maryland</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>15 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Emerging Viral Pathogens Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health</s1>
<s2>Frederick, Maryland</s2>
<s3>USA</s3>
<sZ>7 aut.</sZ>
<sZ>9 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>Zalicus Inc.</s1>
<s2>Cambridge, Massachusetts</s2>
<s3>USA</s3>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
</fA14>
<fA14 i1="05"><s1>United States Army Medical Research Institute of Infectious Diseases</s1>
<s2>Frederick, Maryland</s2>
<s3>USA</s3>
<sZ>12 aut.</sZ>
<sZ>13 aut.</sZ>
</fA14>
<fA20><s1>4885-4893</s1>
</fA20>
<fA21><s1>2014</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>13334</s2>
<s5>354000504837190740</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2014 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>48 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>14-0220025</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Antimicrobial agents and chemotherapy</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Outbreaks of emerging infections present health professionals with the unique challenge of trying to select appropriate pharmacologic treatments in the clinic with little time available for drug testing and development. Typically, clinicians are left with general supportive care and often untested convalescent-phase plasma as available treatment options. Repurposing of approved pharmaceutical drugs for new indications presents an attractive alternative to clinicians, researchers, public health agencies, drug developers, and funding agencies. Given the development times and manufacturing requirements for new products, repurposing of existing drugs is likely the only solution for outbreaks due to emerging viruses. In the studies described here, a library of 290 compounds was screened for antiviral activity against Middle East respiratory syndrome coronavirus (MERS-CoV) and severe acute respiratory syndrome coronavirus (SARS-CoV). Selection of compounds for inclusion in the library was dependent on current or previous FDA approval or advanced clinical development. Some drugs that had a well-defined cellular pathway as target were included. In total, 27 compounds with activity against both MERS-CoV and SARS-CoV were identified. The compounds belong to 13 different classes of pharmaceuticals, including inhibitors of estrogen receptors used for cancer treatment and inhibitors of dopamine receptor used as antipsychotics. The drugs identified in these screens provide new targets for in vivo studies as well as incorporation into ongoing clinical studies.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B02S</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B05C02C</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Autorisation mise sur marché</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Marketing authorization</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Autorisación comercialización</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Indication</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Indication</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Indicación</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Chimiothérapie</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Chemotherapy</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Quimioterapia</s0>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Coronavirus</s0>
<s2>NW</s2>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Coronavirus</s0>
<s2>NW</s2>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Coronavirus</s0>
<s2>NW</s2>
<s5>04</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Infection</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Infection</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Infección</s0>
<s5>05</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Repositionnement</s0>
<s4>INC</s4>
<s5>86</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Syndrome respiratoire du Moyen-Orient</s0>
<s4>CD</s4>
<s5>96</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Middle East respiratory syndrome</s0>
<s4>CD</s4>
<s5>96</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Traitement</s0>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Treatment</s0>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Tratamiento</s0>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Coronaviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Coronaviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Coronaviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Nidovirales</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Nidovirales</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Nidovirales</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Pathologie de l'appareil respiratoire</s0>
<s5>37</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Respiratory disease</s0>
<s5>37</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Aparato respiratorio patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Virose</s0>
<s5>38</s5>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Viral disease</s0>
<s5>38</s5>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Virosis</s0>
<s5>38</s5>
</fC07>
<fN21><s1>265</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
<server><NO>PASCAL 14-0220025 INIST</NO>
<ET>Repurposing of Clinically Developed Drugs for Treatment of Middle East Respiratory Syndrome Coronavirus Infection</ET>
<AU>DYALL (Julie); COLEMAN (Christopher M.); HART (Brit J.); VENKATARAMAN (Thiagarajan); HOLBROOK (Michael R.); KINDRACHUK (Jason); JOHNSON (Reed F.); OLINGER (Gene G. JR); JAHRLING (Peter B.); LAIDLAW (Monique); JOHANSEN (Lisa M.); LEAR-ROONEY (Calli M.); GLASS (Pamela J.); HENSLEY (Lisa E.); FRIEMAN (Matthew B.)</AU>
<AF>Integrated Research Facility, National Institute of Allergy and Infectious Diseases, National Institutes of Health/Frederick, Maryland/Etats-Unis (1 aut., 3 aut., 5 aut., 6 aut., 8 aut., 9 aut., 14 aut.); Department of Microbiology and Immunology, University of Maryland School of Medicine/Baltimore, Maryland/Etats-Unis (2 aut., 4 aut., 15 aut.); Emerging Viral Pathogens Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health/Frederick, Maryland/Etats-Unis (7 aut., 9 aut.); Zalicus Inc./Cambridge, Massachusetts/Etats-Unis (10 aut., 11 aut.); United States Army Medical Research Institute of Infectious Diseases/Frederick, Maryland/Etats-Unis (12 aut., 13 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Antimicrobial agents and chemotherapy; ISSN 0066-4804; Coden AACHAX; Etats-Unis; Da. 2014; Vol. 58; No. 8; Pp. 4885-4893; Bibl. 48 ref.</SO>
<LA>Anglais</LA>
<EA>Outbreaks of emerging infections present health professionals with the unique challenge of trying to select appropriate pharmacologic treatments in the clinic with little time available for drug testing and development. Typically, clinicians are left with general supportive care and often untested convalescent-phase plasma as available treatment options. Repurposing of approved pharmaceutical drugs for new indications presents an attractive alternative to clinicians, researchers, public health agencies, drug developers, and funding agencies. Given the development times and manufacturing requirements for new products, repurposing of existing drugs is likely the only solution for outbreaks due to emerging viruses. In the studies described here, a library of 290 compounds was screened for antiviral activity against Middle East respiratory syndrome coronavirus (MERS-CoV) and severe acute respiratory syndrome coronavirus (SARS-CoV). Selection of compounds for inclusion in the library was dependent on current or previous FDA approval or advanced clinical development. Some drugs that had a well-defined cellular pathway as target were included. In total, 27 compounds with activity against both MERS-CoV and SARS-CoV were identified. The compounds belong to 13 different classes of pharmaceuticals, including inhibitors of estrogen receptors used for cancer treatment and inhibitors of dopamine receptor used as antipsychotics. The drugs identified in these screens provide new targets for in vivo studies as well as incorporation into ongoing clinical studies.</EA>
<CC>002B02S; 002B05C02C</CC>
<FD>Autorisation mise sur marché; Indication; Chimiothérapie; Coronavirus; Infection; Repositionnement; Syndrome respiratoire du Moyen-Orient</FD>
<FG>Traitement; Coronaviridae; Nidovirales; Virus; Pathologie de l'appareil respiratoire; Virose</FG>
<ED>Marketing authorization; Indication; Chemotherapy; Coronavirus; Infection; Middle East respiratory syndrome</ED>
<EG>Treatment; Coronaviridae; Nidovirales; Virus; Respiratory disease; Viral disease</EG>
<SD>Autorisación comercialización; Indicación; Quimioterapia; Coronavirus; Infección</SD>
<LO>INIST-13334.354000504837190740</LO>
<ID>14-0220025</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000004 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 000004 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    SrasV1
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:14-0220025
   |texte=   Repurposing of Clinically Developed Drugs for Treatment of Middle East Respiratory Syndrome Coronavirus Infection
}}

This area was generated with Dilib version V0.6.33.
Data generation: Tue Apr 28 14:49:16 2020. Site generation: Sat Mar 27 22:06:49 2021

	Serveur d'exploration SRAS
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration SRAS

Repurposing of Clinically Developed Drugs for Treatment of Middle East Respiratory Syndrome Coronavirus Infection

Repurposing of Clinically Developed Drugs for Treatment of Middle East Respiratory Syndrome Coronavirus Infection

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri